Feasibility of allogeneic mesenchymal stem cells in pediatric hypoxic-ischemic encephalopathy: Phase I study.

ABSTRACT:

Background

Hypoxic-ischemic encephalopathy (HIE) is one of the leading causes of death and long-term neurological impairment in the pediatric population. Despite a limited number of treatments to cure HIE, stem cell therapies appear to be a potential treatment option for brain injury resulting from HIE.

Aim

To investigate the efficacy and safety of stem cell-based therapies in pediatric patients with HIE.

Methods

The study inclusion criteria were determined as the presence of substantial deficit and disability caused by HIE. Wharton's jelly-derived mesenchymal stem cells (WJ-MSCs) were intrathecally (IT), intramuscularly (IM), and intravenously administered to participants at a dose of 1 × 10⁶/kg for each administration route twice monthly for 2 mo. In diff

SUBMITTER: Kabatas S 

PROVIDER: S-EPMC8176840 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature